ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

The key processes of skin aging are now being understood in sufficient detail that targeted prescription therapies for ...

For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.4 billion, has been gaining attention in the biotechnology sector for its innovative ...

Mojisola Adeyeye, the director-general of the National Agency for Food and Drug Administration and Control (NAFDAC), says the ...

In 2025, sponsors will prioritize contract research organizations (CROs) offering complete and continuous data transparency ...

The U.S. Food and Drug Administration (FDA) published the draft guidance “Protocol Deviations for Clinical Investigations of Drugs, ...

The National Agency for Food and Drug Administration and Control (NAFDAC) said it was seeking financial support to facilitate ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...